Compare Merck & Co., Inc. (MRK) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs DENTSPLY SIRONA Inc — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while DENTSPLY SIRONA Inc trades at $10.66 (market cap $2.19B). The key difference: Merck & Co., Inc. is far larger — about 167.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| MRK | XRAY | |
|---|---|---|
Market Cap | $366.28B | $2.19B |
Sector | Health | Health |
52-Week High | $156.43 | $14.68 |
52-Week Low | $77.60 | $9.64 |
Enterprise Value | $413.04B | $4.26B |
Dividend Yield | 2.29% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.27, down 1.38% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio of 118.77 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples and competitive pressures in the pharma sector. Analyst consensus is bullish with a $156.71 price target, suggesting potential upside from current levels.
XRAY trades at $10.99, down 3.43% on the day, with a mixed technical signal leaning bullish. The company reported a Q2 2026 earnings beat ($0.52 vs. $0.348 expected) but faces fundamental headwinds with negative net income margins and declining revenue trends. Recent news includes participation in the Baird 2026 Global Healthcare Conference and ongoing legal scrutiny regarding fiduciary duties.
The outlook remains challenging due to persistent losses and soft revenue, though the consensus price target of $12.50 suggests modest upside potential. Key risks include execution of the turnaround plan, competitive pressures, and macroeconomic softness in key markets like Europe. Investor sentiment is cautious, reflected in the majority 'Hold' analyst rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
